e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Treatment of tuberculosis and adverse drug reactions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adverse events during treatment for latent tuberculosis infection
C. C. Dobler, G. B. Marks (Sydney, Australia)
Source:
Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Session:
Treatment of tuberculosis and adverse drug reactions
Session type:
Thematic Poster Session
Number:
4404
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. C. Dobler, G. B. Marks (Sydney, Australia). Adverse events during treatment for latent tuberculosis infection. Eur Respir J 2011; 38: Suppl. 55, 4404
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Treatment of latent tuberculosis infection: completion rates and adverse effects
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003
Adverse events in the treatment of multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Adverse reactions to the tuberculosis treatment
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection
Source: ISSN=ISSN 1810-6838, ISBN=, page=190
Year: 2006
Risk of serious adverse reactions during the treatment of new tuberculosis patients
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Adverse effects of treatment in HIV-associated tuberculosis patients in Iran
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Adverse effects of moxifloxacin during tuberculosis treatment
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Adverse reactions of tuberculosis treatment in pacients with and without associated digestive disorders
Source: Eur Respir J 2003; 22: Suppl. 45, 522s
Year: 2003
Completion of treatment for latent tuberculosis infection
Source: Annual Congress 2011 - Clinical tuberculosis
Year: 2011
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019
Year: 2019
Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis.
Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Year: 2021
Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter?
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1592-1594
Year: 2016
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2015; 46: 1397-1406
Year: 2015
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1594-1595
Year: 2016
Outcomes of treatment of latent tuberculosis infection in children with two different regimens
Source: Eur Respir J 2006; 28: Suppl. 50, 487s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept